omadacycline
Sign in to saveAlso known as PTK796, PTK-0796, PTK 0796
Omadacycline, sold under the brand name Nuzyra, is a broad spectrum antibiotic medication belonging to the aminomethylcycline subclass of tetracycline antibiotics. In the United States, it was approved in October 2018, for the treatment of community-acquired bacterial pneumonia and acute skin and skin structure infections.
Key facts
- Drug.image
- Omadacycline.svg
- Drug.image_class
- skin-invert-image
- Drug.pronounce
- oh mad" a sye' kleen
- Drug.tradename
- Nuzyra
- Drug.MedlinePlus
- a618066
- Drug.DailyMedID
- Omadacycline
- Drug.routes_of_administration
- By mouth, intravenous
- Drug.ATC_prefix
- J01
- Drug.ATC_suffix
- AA15
- Drug.legal_US
- Rx-only
- Drug.index2_label
- as salt
- Drug.CAS_number
- 389139-89-3
- Drug.UNII
- 090IP5RV8F
- Drug.PubChem
- 54697325
- Drug.ChemSpiderID
- 20131003
- Drug.KEGG
- D09647
- Drug.KEGG2
- D09940
- Drug.DrugBank
- DB12455
via Wikipedia infobox
~4 min read
Encyclopedic overview
6 sectionsContents
- Mechanism of action
- History
- ''In vitro'' studies
- Clinical trials
- References
- External links
Omadacycline, sold under the brand name Nuzyra, is a broad spectrum antibiotic medication belonging to the aminomethylcycline subclass of tetracycline antibiotics. In the United States, it was approved in October 2018, for the treatment of community-acquired bacterial pneumonia and acute skin and skin structure infections.
==Mechanism of action== The mechanism of action of omadacycline is similar to that of other tetracyclines – inhibition of bacterial protein synthesis. Omadacycline has activity against bacterial strains expressing the two main forms of tetracycline resistance (efflux and ribosomal protection).
Excerpted from Wikipedia’s “omadacycline” article, available under the CC BY-SA 4.0 licence.